Biochemical evaluation of Amlodipne/Ramipril in combination with essential hypertension

The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Amlodipine is a calcium channel-blocking agent with vasodilator activity and Ramipril is ACE inhibitor. The objective of this double-blind, comparative study evaluating the biochemical effects of Amlodipine 5 mg and Ramipril 1.25 mg in combination and as monotherapy in adult patient with essential hypertension, double-blind, comparative study. This study was conducted at the department of Biochemistry, University of Karachi from December 2010 to September 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Amlodopine [5 mg] once daily, Ramipril [1.25 mg] once daily and combination of amlodipine 5 mg with Ramipril 1.25 mg once daily for 8 weeks and at the end of study biochemical evaluation was done. In the patients treated with combination of Amlodipine 5 mg and Ramipril 1.25 mg tablets showed synergetic effect and no significant biochemical effects. We can suggest that good tolerability and no biochemical and hematological effects of combination of Amlodipine 5 mg and Ramipril 1.25 mg to formulate in a single dosage forms [tablet] because it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks